Prostate Cancer News on BioPortfolio

CANCER de la PROSTATE Un cancer faible risque peut en cacher un autre

Ces mdecins de la clinique Mayo ont dcouvert des marqueurs biologiques qui pourraient guider le traitement du cancer de la prostate des altrations gntiques dans le cancer de la prostate faible risque tel que diagnostiqu par biopsie l&039;aiguille po...

Harpoons IPO Spears $76M as Prostate Cancer Drug Continues Testing

Cancer immunotherapy developer Harpoon Therapeutics is the latest biotech to enter the public markets raising approximately $76 million in an initial public offering. South San Francisco CAbased Harpoon offered 5.4 million shares Thursday evening priced at...

$ARVN Announces Poster Presentation at ASCOGU19. To Highlight ARV110 PROTAC Protein Degrader for the Treatment of Prostate Cancer FEB. 14 httpsglobenewswire.comnewsrelease2019020717137410enArvinasAnnouncesPosterPresentationatASCO201

$ARVN Announces Poster Presentation at ASCOGU19. To Highlight ARV110 PROTAC™ Protein Degrader for the Treatment of Prostate Cancer FEB. 14 httpsglobenewswire.comnewsrelease2019020717137410enArvinasAnnouncesPosterPresentationatASCO2019Genitouri...

Prostate Cancer Prediction Looks to Machine Learning for Accuracy Boost

Diagnosing prostate cancer PCa has continually faced hurdles that have been difficult to overcome. The current diagnostic standard the prostatespecific antigen or PSA test has many limitationsas Richard J. Ablin PhD discoverer of PSA in 1970 has vociferous...

New prostate cancer prediction tool has unmatched accuracy

A team of researchers from the Icahn School of Medicine at Mount Sinai and Keck School of Medicine at the University of Southern California have developed a novel machinelearning framework that distinguishes between low and highrisk prostate cancer with mo...

Medicare Won't Pay for Prostate Cancer Risk Test

Flaws in clinical studies were cited by a Medicare contractor in rejecting reimbursement for 4Kscore a blood test that predicts the likelihood of aggressive prostate cancer. Medscape Medical News

Leap Therapeutics nets $12.4mm in public offering

Leap Therapeutics Inc. immunooncology netted $12.4mm through a public offering of 7.5mm common shares including the overallotment at $1.75. Investors also received sevenyear warrants to purchase another 6.57mm shares at $1.95. Money will support general co...

Researchers reveal prostate tumors 'fed' by fatty acids

University of Melbourne An international multidisciplinary study initiated by Melbourne scientists has shown a link between prostate cancer and the uptake of fatty acids by cancer cells. The findings point to a possible therapeutic target for this common c...

Pages